Group 1 - The core viewpoint of the article highlights the successful debut of Changfeng Pharmaceutical Co., Ltd. on the Hong Kong Stock Exchange, with a significant initial price surge of 219% [3] - The company issued approximately 41.2 million H-shares, with a public offering that was oversubscribed by nearly 6,697 times, resulting in a very low winning rate of 1% for those who applied for one lot [3] - The international placement was also oversubscribed by 11.7 times, raising a net amount of HKD 525 million [3] Group 2 - Changfeng Pharmaceutical focuses on the research, development, production, and commercialization of inhalation technology and inhalation drugs, specifically targeting respiratory diseases [3] - In the first quarter of this year, the company's revenue decreased by 2.7% year-on-year to HKD 136 million, while net profit increased more than twofold to HKD 12.815 million [3]
简讯：超额6,700倍 长风药业午收升181%